MedTrace Logo

Contrast Ultrasound Assessment of Perfusion Changes After Peripheral Artery Revascularization

NCT02877563 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2018-08-23

No results posted yet for this study

Summary

This study represents an important step to validate the use of contrast-enhanced ultrasound (CEU) as a clinical research tool that can be used as a biologic readout of new therapies for Peripheral Artery Disease (PAD), and as a clinically-reasonable method for assessing impact of revascularization. The primary aim is to establish that CEU limb perfusion imaging can be used to accurately assess therapeutic improvements in tissue perfusion that are linked to symptom improvement.

Conditions

Interventions

OTHER

Contrast ultrasound perfusion imaging of the limb

Contrast enhanced ultrasound imaging at rest and during contractile exercise will be performed prior to revascularization and 3-4 weeks after revascularization.

Sponsors & Collaborators

  • Oregon Health and Science University

    lead OTHER

Eligibility

Min Age
19 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2019-12-31
Completion
2019-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02877563 on ClinicalTrials.gov